Vesalius Research Center, K.U. Leuven, Leuven, Belgium.
Am J Respir Crit Care Med. 2010 Mar 1;181(5):486-93. doi: 10.1164/rccm.200909-1364OC. Epub 2009 Dec 10.
Genome-wide association studies have identified genetic variants in the nicotinic acetylcholine receptor (nAChR) on chromosome 15q24/25 as a risk for nicotine dependence, lung cancer, and chronic obstructive pulmonary disease (COPD). Assessment of bronchial obstruction by spirometry, typically used for diagnosing COPD, fails, however, to detect emphysema.
To determine the association of the 15q24/25 locus with emphysema.
The rs1051730 variant on 15q24/25 was genotyped in two independent white cohorts of 661 and 456 heavy smokers. Participants underwent pulmonary function tests and computed tomography (CT) of the chest, and took questionnaires assessing smoking behavior and health status.
The rs1051730 A-allele correlated with reduced FEV(1) and with increased susceptibility for bronchial obstruction with a pooled odds ratio (OR) of 1.33 (95% confidence interval [CI] = 1.11-1.61; P = 0.0026). In both studies a correlation between the rs1051730 A-allele and lung diffusing capacity (Dl(CO)) and diffusing capacity per unit alveolar volume (Kco) was observed. Consistently, the rs1051730 A-allele conferred increased risk for emphysema as assessed by CT (P = 0.0097 and P = 0.019), with a pooled OR of 1.39 (CI = 1.15-1.68; P = 0.00051). Visual emphysema scores and scores based on densities quantified on CT were more pronounced in A-allele carriers, indicating that rs1051730 correlates with the severity of emphysema.
The 15q24/25 locus in nAChR is associated with the presence and severity of emphysema. This association was independent of pack-years smoking, suggesting that nAChR is causally involved in alveolar destruction as a potentially shared pathogenic mechanism in lung cancer and COPD.
全基因组关联研究已经确定了 15 号染色体上的烟碱型乙酰胆碱受体(nAChR)上的遗传变异是尼古丁依赖、肺癌和慢性阻塞性肺疾病(COPD)的风险因素。肺功能测试(通常用于诊断 COPD)评估支气管阻塞,但未能检测肺气肿。
确定 15q24/25 基因座与肺气肿的关联。
在两个独立的白人队列中,对 661 名和 456 名重度吸烟者进行了 15q24/25 上的 rs1051730 变异体的基因分型。参与者接受了肺功能测试和胸部计算机断层扫描(CT)检查,并填写了评估吸烟行为和健康状况的问卷。
rs1051730A 等位基因与 FEV1 降低相关,与支气管阻塞的易感性增加相关,合并优势比(OR)为 1.33(95%置信区间[CI] = 1.11-1.61;P = 0.0026)。在两项研究中,rs1051730A 等位基因与肺弥散能力(Dl(CO))和单位肺泡容积弥散能力(Kco)之间存在相关性。一致地,rs1051730A 等位基因赋予 CT 评估的肺气肿风险增加(P = 0.0097 和 P = 0.019),合并 OR 为 1.39(CI = 1.15-1.68;P = 0.00051)。A 等位基因携带者的视觉肺气肿评分和基于 CT 密度量化的评分更为明显,表明 rs1051730 与肺气肿的严重程度相关。
nAChR 上的 15q24/25 基因座与肺气肿的存在和严重程度相关。这种关联与吸烟包年数无关,表明 nAChR 可能作为肺癌和 COPD 的潜在共同致病机制,参与肺泡破坏。